BRPI0517559A - composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos - Google Patents

composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos

Info

Publication number
BRPI0517559A
BRPI0517559A BRPI0517559-3A BRPI0517559A BRPI0517559A BR PI0517559 A BRPI0517559 A BR PI0517559A BR PI0517559 A BRPI0517559 A BR PI0517559A BR PI0517559 A BRPI0517559 A BR PI0517559A
Authority
BR
Brazil
Prior art keywords
compounds
inhibitors
modulated
therapeutic
preparation
Prior art date
Application number
BRPI0517559-3A
Other languages
English (en)
Inventor
Adrian Wai-Hing Cheung
Kshitij Chhabilbhai Thakkar
Weiya Yun
Steven Joseph Berthel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0517559A publication Critical patent/BRPI0517559A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS, PROCESSO PARA A SUA PREPARAçãO, MéTODO PARA O TRATAMENTO TERAPêUTICO E/OU PROFILATICO DE ENFERMIDADES QUE SãO MODULADAS POR INIBIDORES DE PTP-1B E UTILIZAçãO DOS COMPOSTOS. A presente invenção relaciona-se com compostos da fórmula (I) em que R˜ , R� e X são tais como definidos na descrição e reivindicações. Os compostos da presente invenção são inibidores de PTP-1E e podem ser utilizados como medicamentos.
BRPI0517559-3A 2004-11-09 2005-11-02 composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos BRPI0517559A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62628804P 2004-11-09 2004-11-09
US71526005P 2005-09-08 2005-09-08
PCT/EP2005/011682 WO2006050843A1 (en) 2004-11-09 2005-11-02 Aminoquinazolines compounds

Publications (1)

Publication Number Publication Date
BRPI0517559A true BRPI0517559A (pt) 2008-10-14

Family

ID=36035951

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517559-3A BRPI0517559A (pt) 2004-11-09 2005-11-02 composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos

Country Status (10)

Country Link
US (2) US20060211715A1 (pt)
EP (1) EP1812409A1 (pt)
JP (1) JP2008519083A (pt)
KR (1) KR100915481B1 (pt)
AU (1) AU2005304040B2 (pt)
BR (1) BRPI0517559A (pt)
CA (1) CA2586105A1 (pt)
MX (1) MX2007005408A (pt)
RU (1) RU2382034C2 (pt)
WO (1) WO2006050843A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
CN101068762B (zh) * 2004-08-17 2010-05-05 卫材R&D管理有限公司 制备二溴氟苯衍生物的方法
JP2009242240A (ja) * 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
JP5209254B2 (ja) * 2007-08-30 2013-06-12 日本曹達株式会社 置換フェノキシアザビシクロオクタン誘導体の製造方法
US8835445B2 (en) 2010-06-02 2014-09-16 Trius Therapeutics, Inc. Dihydrofolate reductase inhibitors
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
HUE036220T2 (hu) * 2011-05-18 2018-06-28 Janssen Sciences Ireland Uc Kinazolin származékok vírusfertõzések és további betegségek kezelésére
US9884828B2 (en) 2011-05-23 2018-02-06 Imago Pharmaceuticals, Inc. Substituted cinnolines as inhibitors of LRRK2 kinase activity
TW201311149A (zh) * 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
SG195200A1 (en) * 2011-06-29 2013-12-30 Otsuka Pharma Co Ltd Quinazolines as therapeutic compounds and related methods of use
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
KR101270467B1 (ko) 2012-10-09 2013-06-03 박배근 비스포스포네이트 또는 이의 약학적으로 허용되는 염을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
BR112015019624A2 (pt) * 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
KR102225233B1 (ko) 2013-02-21 2021-03-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
MX366481B (es) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
MY188071A (en) 2013-05-24 2021-11-16 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
CN109369643B (zh) 2013-06-27 2021-05-18 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
PL3097102T3 (pl) * 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
WO2018060317A1 (en) 2016-09-29 2018-04-05 Janssen Sciences Ireland Uc Pyrimidine prodrugs for the treatment of viral infections and further diseases
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN113301962A (zh) * 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的杂环nlrp3调节剂
JP7506080B2 (ja) * 2019-01-14 2024-06-25 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３モジュレーター
JP7373571B2 (ja) * 2019-01-14 2023-11-02 イネイト・テューマー・イミュニティ・インコーポレイテッド がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
EP3811945A1 (en) 2019-10-25 2021-04-28 UMC Utrecht Holding B.V. Compounds for treating and preventing growth hormone receptor-dependent conditions
TW202435887A (zh) 2023-03-01 2024-09-16 瑞士商諾華公司 用於治療疾病或障礙的氫喹唑啉衍生物
WO2024249763A2 (en) * 2023-06-02 2024-12-05 University Of Florida Research Foundation, Incorporated Prmt5 synthetic lethal inhibitors targeting mtap deleted cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023369A1 (de) * 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
ES2207657T3 (es) * 1995-02-27 2004-06-01 F. Hoffmann-La Roche Ag Pirrolderivados de dioxopirrolo.
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
AU2960599A (en) * 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
JP2000038350A (ja) * 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
EP1411949A4 (en) * 2001-06-28 2004-11-24 Essential Therapeutics Inc 8/17 HETEROCYCLIC COMPOUNDS AND THEIR USES AS D-ALANYLE-D-ALANINE LIGASE INHIBITORS
US7262200B2 (en) * 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
ATE372324T1 (de) * 2003-04-30 2007-09-15 Inst For Pharm Discovery Inc Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen

Also Published As

Publication number Publication date
RU2007121507A (ru) 2008-12-20
US20060211715A1 (en) 2006-09-21
AU2005304040B2 (en) 2009-04-23
JP2008519083A (ja) 2008-06-05
EP1812409A1 (en) 2007-08-01
RU2382034C2 (ru) 2010-02-20
MX2007005408A (es) 2007-05-16
WO2006050843A1 (en) 2006-05-18
AU2005304040A1 (en) 2006-05-18
US20090105477A1 (en) 2009-04-23
CA2586105A1 (en) 2006-05-18
KR100915481B1 (ko) 2009-09-03
KR20070085843A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
BRPI0517559A (pt) composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos
BR0317926A (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e utilização dos mesmos
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BR0316091A (pt) Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
BR0317931A (pt) Compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização dos compostos
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BR0307665A (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
BRPI0516842A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BRPI0717367B8 (pt) di-hidropirazolonas substituídas, seus usos e seu processo de preparação, e medicamento
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BRPI0413582A (pt) compostos, composições e métodos para inibir a atividade de proteasome
BR0215396A (pt) Compostos, processo para a manufatura de compostos, composições farmacêuticas, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com "dpp-iv" e utilização dos compostos
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
BRPI0606675A2 (pt) agonista receptor de neuropeptìdio-2, composições farmacêuticas que compreendem o mesmo, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
BRPI0607861A2 (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
BR0112580A (pt) Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
BRPI0519620A2 (pt) compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento terapÊutico e/ou profilÁtico de enfermidades que sço moduladas por agonistas alfa-lxr e/ou beta-lxr e utilizaÇço desses compostos
BR0313946A (pt) Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2209 DE 07/05/2013.